➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Express Scripts
Johnson and Johnson
Medtronic

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,065,952


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,065,952
Title:Valbenazine salts and polymorphs thereof
Abstract: Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.
Inventor(s): McGee; Kevin (San Diego, CA), Zook; Scott (San Diego, CA), Carr; Andrew (Cambridge, GB), Bonnaud; Thierry (Cambridge, GB)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:15/338,214
Patent Claims: 1. A crystal form of the compound of Formula I: ##STR00006## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of: a) 6.3, 17.9, and 19.7.degree..+-.0.2.degree.; or of: b) 6.3, 18.3, and 19.8.degree..+-.0.2.degree..

2. A crystal form of the compound of Formula I: ##STR00007## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 5.7, 15.3, and 22.5.degree..+-.0.2.degree..

3. A crystal form of the compound of Formula I: ##STR00008## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 6.2, 10.4, and 20.2.degree..+-.0.2.degree..

4. A crystal form of the compound of Formula I: ##STR00009## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 6.7, 7.9, and 23.7.degree..+-.0.2.degree..

5. A crystal form of the compound of Formula I: ##STR00010## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 6.8, 5.4 and 8.0.degree..+-.0.2.degree..

6. Amorphous: ##STR00011## having an X-Ray diffraction pattern substantially as shown in FIG. 19.

7. A crystal form of the compound of Formula II: ##STR00012## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 7.2, 9.2, and 18.0.degree..+-.0.2.degree..

8. A crystal form of the compound of Formula II: ##STR00013## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 4.8, 13.3, and 24.9.degree..+-.0.2.degree..

9. Amorphous: ##STR00014## having an X-Ray diffraction pattern substantially as shown in FIG. 26.

10. A pharmaceutical composition comprising the crystal form of claim 1 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein the composition is formulated for oral administration.

12. The pharmaceutical composition of claim 10, wherein the composition is formulated as a single dosage form.

13. A method of ameliorating one or more symptoms of a hyperkinetic disorder, comprising administering the crystal form of claim 1.

14. The method according to claim 13, wherein the hyperkinetic disorder is Huntington's disease, tardive dyskinesia, Tourette's syndrome, dystonia, hemiballismus, chorea, or tics.

15. The method according to claim 14, wherein the hyperkinetic disorder is tardive dyskinesia.

16. The method according to claim 14, wherein the hyperkinetic disorder is Tourette's syndrome.

17. A method for inhibiting vesicular monoamine transporter isoform 2 in a subject comprising administering to the subject the crystal form of claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Dow
AstraZeneca
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.